Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 168 | 168 | 168 |
Full Text Views | 19 | 19 | 19 |
PDF Downloads | 19 | 19 | 19 |
Studies describing the global burden of meningitis often exclude HIV- or tuberculosis (TB)-related etiologies, thereby presenting a limited view of meningitis etiology in low- and middle-income countries. This study provides an updated evaluation of the etiology of meningitis and treatment outcomes in Uganda given advancements in molecular and TB diagnostics. We conducted a prospective observational cohort study from December 2018 to October 2023, for which adults with suspected meningitis were recruited from three referral hospitals in Uganda. We used a comprehensive diagnostic algorithm to determine microbiological etiologies of cases. Participants were followed through hospital discharge, and mortality was summarized by meningitis etiology. We enrolled 1,577 participants with suspected meningitis, of whom 96% (n = 1,511/1,577) had HIV infection and 51% (n = 772/1,577) were antiretroviral therapy naive. The median CD4 cell count was 39 cells/µL (interquartile range: 14–97 cells/µL). Cryptococcal meningitis was the most frequently diagnosed etiology of meningitis (62%) followed by TB meningitis (21%). Inpatient mortality was highest among participants diagnosed with possible TB meningitis (32%) followed by probable TB meningitis (29%) and bacterial meningitis (24%). Among the 4% (n = 66/1,577) of HIV-seronegative participants, TB meningitis was the most frequently (38%) diagnosed cause of meningitis. Despite improvements in access to HIV therapy, cryptococcal meningitis and tuberculous meningitis persist as the most common etiologies of meningitis in Uganda. Improved access to meningitis diagnostics and treatments is critically needed to mitigate the morbidity and mortality, particularly in the resource-limited settings of HIV and TB endemic regions.
Financial support: This research was supported by the
Disclosures: The study conformed to U.S. and international standards of Good Clinical Practice, the Declaration of Helsinki, and international ethical guidelines for biomedical research involving human subjects. The parent study protocols were approved by the Human Subjects Protection Board at the Mulago Research and Ethics Committee, the Uganda National Council for Science and Technology, and the University of Minnesota Institutional Review Board. All participants or surrogates (in cases of incapacity) provided written informed consent before enrollment. The funder had no role in study conduct or data analysis. Data were accessible to all of the authors.
Current contact information: Timothy Mugabi, Suzan Namombwe, Elizabeth Nalintya, Laura J. Nsangi, Mable Kabahubya, Sarah M. Najjuka, Samuel Okurut, Olivie C. Namuju, Kisakye D. Kabbale, Bakka Wilber, Lillian Tugume, David B. Meya, and Jayne Ellis, Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda, E-mails: tmugabi@idi.co.ug, snamombwe@idi.co.ug, enalintya@idi.co.ug, lnsangi@idi.co.ug, mkabahubya@idi.co.ug, najjukasarah@gmail.com, okuruts@gmail.com, cnamuju@idi.co.ug, dikisakye@gmail.com, bakkawilber@gmail.com, lilliqntugume18@gmail.com, david.meya@gmail.com, and jayne.ellis1@lshtm.ac.uk. Biyue Dai, Nathan C. Bahr, David R. Boulware, and Radha Rajasingham, Division of Infectious Diseases & International Medicine, Department of Medicine, University of Minnesota, Minneapolis, MN, E-mails: biydai@umn.edu, bahrx026@umn.edu, boulw001@umn.edu, and radha@umn.edu. Enos Kigozi, Samuel Jjunju, and Conrad Muzoora, Department of Medicine, Mbarara University of Science and Technology, Mbarara, Uganda, E-mails: kigozi.enos@gmail.com, junjusamuel93@gmail.com, and conradmuzoora@yahoo.com. Martineau Louine and Michael R. Wilson, Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, CA, E-mails: martineau.louine@ucsf.edu and michael.wilson@ucsf.edu. Fiona V. Cresswell, MRC/UVRI-LSHTM Uganda Research Unit, Entebbe, Uganda, and Center for Global Health and Infection, Brighton and Sussex Medical School, Brighton, United Kingdom, E-mail: fiona.cresswell@lshtm.ac.uk.
Past two years | Past Year | Past 30 Days | |
---|---|---|---|
Abstract Views | 168 | 168 | 168 |
Full Text Views | 19 | 19 | 19 |
PDF Downloads | 19 | 19 | 19 |